|Last Price$181.66||Day Change (%)2.89%|
|Open Price$177.44||Day Change ($)5.10|
|Day Range176.71–182.61||52-Week Range127.10–196.47|
As of Fri 9/30/2016 5:00:00 PM | USD
Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016
Global Non-Invasive Prenatal Testing Market Growth of 17.44% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: BGI Genomics, Illumina , LifeCodexx - Research and Markets
Genome Editing Global Market to Grow 31.1% by 2022 - Increased R&D Expenditure in Biotechnology & Pharmaceutical Industries - Research and Markets
Global Prenatal & Maternal Diagnostic Market Analysis to 2021 - Research and Markets
Dr. Scott Kahn Joins Optra Health as Chief Strategy Advisor
Next Generation Sequencing (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) Markets 2015-2020 - Research and Markets
Transplant Diagnostic Market to 2024 - Analysis By Technology, By Product And Segment Forecasts of the $895 Million Market - Research and Markets
Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...
Continued technology advancements and market expansion support Illumina's narrow moat.
Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.